Gyre Therapeutics, Inc.
GYRE
$8.60
-$0.215-2.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 27.87M | 25.49M | 25.23M | 27.17M | 27.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.87M | 25.49M | 25.23M | 27.17M | 27.15M |
| Cost of Revenue | 1.18M | 958.00K | 770.00K | 979.00K | 1.25M |
| Gross Profit | 26.70M | 24.53M | 24.46M | 26.19M | 25.90M |
| SG&A Expenses | 22.32M | 17.52M | 17.84M | 15.94M | 26.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.21M | 21.26M | 21.96M | 19.10M | 32.34M |
| Operating Income | 663.00K | 4.23M | 3.26M | 8.07M | -5.19M |
| Income Before Tax | 772.00K | 3.93M | 6.04M | 12.48M | -100.28M |
| Income Tax Expenses | 203.00K | 1.07M | 1.50M | 2.55M | 699.00K |
| Earnings from Continuing Operations | 569.00K | 2.86M | 4.54M | 9.94M | -100.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -668.00K | -1.73M | -1.01M | -2.40M | -29.00K |
| Net Income | -99.00K | 1.12M | 3.53M | 7.53M | -101.01M |
| EBIT | 663.00K | 4.23M | 3.26M | 8.07M | -5.19M |
| EBITDA | 1.13M | 4.69M | 3.50M | 8.50M | -4.88M |
| EPS Basic | 0.00 | 0.01 | 0.04 | 0.09 | -1.39 |
| Normalized Basic EPS | 0.00 | 0.01 | 0.03 | 0.06 | -0.13 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | 0.09 | -1.39 |
| Normalized Diluted EPS | 0.00 | 0.01 | 0.03 | 0.06 | -0.13 |
| Average Basic Shares Outstanding | 85.95M | 85.64M | 85.50M | 83.27M | 72.56M |
| Average Diluted Shares Outstanding | 85.95M | 102.64M | 104.33M | 83.27M | 72.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |